Literature DB >> 10860903

Determinants of virological response to antiretroviral therapy: implications for long-term strategies.

S G Deeks1.   

Abstract

A variety of factors can contribute to the failure of combination antiretroviral therapy to durably suppress viral replication in patients infected with human immunodeficiency virus (HIV). Patients who have a low CD4(+) T cell count or high plasma viral load before therapy is initiated are at high risk for subsequent virological failure. Previous therapy is also a strong determinant of subsequent virological response, presumably because of pre-existing viral resistance. Drug exposure, as determined by adherence, drug absorption, and drug metabolism, has a significant impact on future long-term virological responses. Although definitive proof is lacking, some tissues may have limited drug penetration, thus allowing for ongoing viral replication. Understanding why combination therapy fails for HIV-infected patients may allow clinicians to individualize treatment strategies. Unfortunately, almost any factor (drug, host, or viral) that leads to virological failure of an initial combination regimen is likely to persist-and perhaps become more challenging-once a salvage regimen is initiated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10860903     DOI: 10.1086/313855

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  26 in total

1.  Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis.

Authors:  Susan Swindells; Hongyu Jiang; A Lisa Mukherjee; Mark Winters; Ronald J Bosch; David Katzenstein
Journal:  HIV Clin Trials       Date:  2011 Mar-Apr

2.  In vitro development of resistance to human immunodeficiency virus protease inhibitor GW640385.

Authors:  P J Yates; R Hazen; M St Clair; L Boone; M Tisdale; R C Elston
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

3.  Resistance evolution in HIV - modeling when to intervene.

Authors:  Liliana Mabel Peinado Cortes; Ryan Zurakowski
Journal:  Proc Am Control Conf       Date:  2012

4.  Quantification of intrinsic residual viral replication in treated HIV-infected patients.

Authors:  C Fraser; N M Ferguson; R M Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

5.  Incomplete viral suppression and mortality in HIV patients after antiretroviral therapy initiation.

Authors:  Jennifer S Lee; Stephen R Cole; David B Richardson; Dirk P Dittmer; William C Miller; Richard D Moore; Mari Kitahata; Christopher Mathews; Kenneth Mayer; Elvin Geng; Chad J Achenbach; Joseph J Eron
Journal:  AIDS       Date:  2017-09-10       Impact factor: 4.177

6.  Zidovudine phosphorylation determined sequentially over 12 months in human immunodeficiency virus-infected patients with or without previous exposure to antiretroviral agents.

Authors:  P G Hoggard; J Lloyd; S H Khoo; M G Barry; L Dann; S E Gibbons; E G Wilkins; C Loveday; D J Back
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

7.  High prevalence of M184 mutation among patients with viroimmunologic discordant responses to highly active antiretroviral therapy and outcomes after change of therapy guided by genotypic analysis.

Authors:  Emanuele Nicastri; Loredana Sarmati; Gabriella d'Ettorre; Saverio G Parisi; Lucia Palmisano; Clementina Galluzzo; Marco Montano; Ilaria Uccella; Roberta Amici; Francesca Gatti; Vincenzo Vullo; Ercole Concia; Stefano Vella; Massimo Andreoni
Journal:  J Clin Microbiol       Date:  2003-07       Impact factor: 5.948

8.  Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial.

Authors:  Edward M Gardner; Katherine H Hullsiek; Edward E Telzak; Shweta Sharma; Grace Peng; William J Burman; Rodger D MacArthur; Margaret Chesney; Gerald Friedland; Sharon B Mannheimer
Journal:  AIDS       Date:  2010-01-28       Impact factor: 4.177

9.  The relationship between resistance and adherence in drug-naive individuals initiating HAART is specific to individual drug classes.

Authors:  Lily W Y Tam; Celia K S Chui; Chanson J Brumme; David R Bangsberg; Julio S G Montaner; Robert S Hogg; P Richard Harrigan
Journal:  J Acquir Immune Defic Syndr       Date:  2008-11-01       Impact factor: 3.731

10.  The Antiviral Activity of Approved and Novel Drugs against HIV-1 Mutations Evaluated under the Consideration of Dose-Response Curve Slope.

Authors:  Shuai Chang; Daomin Zhuang; Wei Guo; Lin Li; Wenfu Zhang; Siyang Liu; Hanping Li; Yongjian Liu; Zuoyi Bao; Jingwan Han; Hongbin Song; Jingyun Li
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.